Slide 1: Regulation 30 filing cover letter
CIN:L2410TG9P7V - Vimta Labs Limited Vimta Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051 Telangana, India T: +91 4027264141 F : +91 40 2726 3657 Driven by Quality. Inspired by Science. VLL\SE\076\2024-25 Date: 24.01.2025 B S E Limited, National Stock Exchange of India Limited, P
Slide 2: Investor Presentation Q3 & 9M FY25
Vimta Labs Limited Investor Presentation Q3 & 9M FY25
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table of Content
Table of Content Q3 & 9M FY25 Earnings Company Overview Industry Landscape Our Competitive Advantage Way Forward
Slide 5: Q3 & 9M FY25 Earnings
Q3 & 9M FY25 Earnings Q3 & 9M FY25 Highlights Key Metrics: Q3 & 9M FY25 Profit & Loss Statement Balance Sheet Financial Track Record Shareholding Pattern 4
Slide 6: Q3 FY25 Highlights
Q3 FY25 Highlights Rs 911 Mn Rs 343 Mn Rs 239 Mn Margin 37.6% Total Income EBITDA PBT Rs 7.9 Rs 657 Mn Rs 175 Mn Margin 19.2% EPS CAPEX PAT 5
Slide 7: 9M FY25 Highlights
9M FY25 Highlights Rs 2,521 Mn Rs 915 Mn Rs 640 Mn Margin 36.3% Total Income EBITDA PBT Rs 21.8 Rs 958 Mn Rs 484 Mn Margin 19.2% EPS CAPEX PAT 0.03x Rs 113 Mn Rs 180 Mn (December 31st 2024) (December 31st 2024) Debt to Equity Ratio Total Debt Cash and Cash Equivalents 6
Slide 8: Key Metrics: Q3 FY25
Key Metrics: Q3 FY25 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) (In ₹) EBIDTA EBIDTA Margin PAT PAT Margin 19.2% 21.1% 39.4% 43.0% YoY YoY 200 YoY 19.9% 25% 175 16.3% 5 20% 37.6% 150 35.8% 125 15% 32.7% 100 10% 75 50 5% 246 306 343 5.5 7.7 7.9
Slide 9: Key Metrics: 9M FY25
Key Metrics: 9M FY25 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) (In ₹) EBIDTA EBIDTA Margin PAT PAT Margin 15.0% 28.1% 525 39.0% YoY YoY YoY 25% 500 475 450 19.2% 36.3% 15.9% 425 20% 32.6% 400 375 350 325 15% 300 275 250 225 10% 200 175 150 125
Slide 10: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q3 FY25 Q3 FY24 YoY (%) Q2 FY25 QoQ(%) 9M FY25 9M FY24 YoY (%) Revenue from Operations 899 746 847 2,495 2,159 Other Income 12 7 7 26 33 Total Income 911 753 21.1% 854 6.7% 2,521 2,192 15.0% Material and Testing Costs 204 151 182 529 440 Cost of lab setup 2
Slide 11: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA Margin PAT & PAT Margin 36% 19% 29% 31% 28% 15% 15% 25% 13% 18% 4% 10% 11.9% 22.4% 43.2% 1,837 2,115 2,797 3,216 3,223 2,521 330 538 817 984 908 915 214 413 482 410 484 CAGR CAGR 68 CAGR FY20 FY21 FY22 FY23 FY24 9MFY25 F
Slide 12: Shareholding Pattern
Shareholding Pattern Shareholding as on 31st December 2024 Share Information as on 31st December 2024 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 2,170.24 Others % free-float 63.24% Promoters 58.3% Free-float market cap (INR Cr) 1,372.49 36.8% Total Debt (INR Mn) 113 Cash & Cash Equiv
Slide 13: Company Overview
Company Overview Vimta at a Glance Our Journey Services Geographical Presence Management 12
Slide 14: Vimta at a Glance
Vimta at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high- quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, sm
Slide 15: Our Journey
Our Journey Infrastructure People Investment Capabilities Revenue s Pharma & Biopharma: Discovery & 2024 600,000+ ft2 1300+ 492 M development services; Food; Environment; Electronics Testing 3,216 M Analytical – Pharma, Biopharma & 2015 400,000+ ft2 1000+ 580 M Food; Clinical Research; Preclinical;
Slide 16: Our offerings
Our offerings Drug discovery Food & Agri Electronics & Environment and development Testing Electricals Testing & services Testing Consultancy 15
Slide 17: Drug discovery and development services
1. Drug discovery and development services Offerings Pharma Analytical Clinical Research Preclinical Research Industry Pharmaceuticals, Biologics, Medical Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health Device, Agrochemical, Speciality Chemicals Accreditations & DCA, USFDA
Slide 18: Food & Agri Testing
2. Food & Agri Testing Industry Food Manufacturing & Processing, Cultivation, Export, Retail, Neutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed No. of Locations 7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida) Accreditations & • FSSAI, ISO 17025, BIS, APEDA, EI
Slide 19: Electricals & Electronics Testing & Certification
3. Electricals & Electronics Testing & Certification Industry Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries No. of Laboratories 1 (Hyderabad) Accre
Slide 20: Environment Testing & Consultancy Services
4. Environment Testing & Consultancy Services Industry Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc. No. of Locations 4 (Hyderabad, Chennai, Kolkata and Noida) Accreditations & MoEF, ISO 17025, QCI/NABET, OSHAS 45000 Regulatory Approvals Post proje
Slide 21: Geographical Presence
Geographical Presence Hyderabad (Headquarters) Food Pharma Electronics & Electrical Environment Food Environment Electrical and Electronics Hyderabad Hyderabad Hyderabad Ahmedabad Chennai Noida Noida Mumbai (NFL) Kolkata Nashik Bengaluru Nellore 20
Slide 22: Key Management Team
Key Management Team S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Harriman Vungal Executive Chairman Managing Director Executive Director Executive Director - Operations Dr. S P Vasireddi is a Scientist – Technocrat Harita has close to 25 years of experience Sreenivas’s core competencies inclu
Slide 23: Industry Landscape
Industry Landscape Market Opportunity Factors Driving Industry Growth 22
Slide 24: Market Opportunity
Markets Opportunity Pharmaceutical & Preclinical Food Testing Environment Testing Electronics Testing Biopharmaceuticals 957.6 127.3 40.5 20.2 13.4 76.6 11.1 (USD Bn) 19.5 6.8 Global 405.5 2020 | 2028 2023 | 2028 2022 | 2032 2022 | 2030 2021 | 2031 CAGR: 11.3% CAGR: 10.7% CAGR: 7.5% CAGR: 7.8% CAGR:
Slide 25: Factors Driving Industry Growth
Factors Driving Industry Growth Drug Food Electrical & Environment Discovery & Testing Electronics Testing Development Testing Increasing demand for Growing international Surge in demand for Increase in regulations to new drug innovations, food regulations, certification services of address the grow
Slide 26: Our Competitive Advantage
Our Competitive Advantage Our Position in the CRTO Landscape Our Strength 25
Slide 27: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape Pharma Analytical Food Testing #1 in India #1 in India Customers – 90% of India top 20 Serving 7 of India’s top 10 food companies 36% revenues from overseas The only private EU commission approved lab in India Clinical Research Preclinical Among the most reputed CR
Slide 28: Our Strengths
Our Strengths Compliance Infrastructure Innovations Strong culture of quality and Unparalleled lab infrastructure in the Continuous addition of services and compliance country. Gold LEED certified Vivarium evolving excellence Customer Centricity Knowledge Long term partnerships Multi-disciplinary, k
Slide 29: Way Forward
Way Forward Our Key Growth Drivers & Strategies 28
Slide 30: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable Core business Core operational Best markets strategies strategies practices ✓ Growth momentum ✓ Capacity expansions ✓ Operational excellence ✓ Good corporate in markets governance ✓ Service innovations ✓ Hiring right talent ✓ Growing demand ✓ Risk manag
Slide 31: Thank you
Thank you VIMTA LABS LIMITED INVESTOR RELATIONS AT Registered Office Plot NSE: VIMTALABS Vimta Labs Ltd. Siddesh Chawan Siddesh.Chawan@in.ey.com Plot #142, IDA Phase 2 BSE: 524394 mdoffice@vimta.com Cherlapally, Hyderabad Advait Bhadekar ISIN: INE579C01029 Advait.Bhadekar@in.ey.com Telangana, India.